Related Experiment Video

Updated: Mar 11, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.3K

Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM

Mohamed Bouattour1, Olivier Soubrane2, Armand de Gramont3

  • 1Department of Hepatology, Beaujon University Hospital, 100 boulevard du Général Leclerc, Clichy, 92110, France. mohamed.bouattour@aphp.fr.

Trials
|November 27, 2016
PubMed

Insights

Sorafenib, an antiangiogenic drug, did not improve outcomes for hepatocellular carcinoma patients in adjuvant therapy. This large trial

Area of Science:

  • Hepatobiliary cancers
  • Clinical oncology
  • Drug efficacy studies

Background:

  • Sorafenib, a targeted therapy, was investigated for adjuvant treatment of hepatocellular carcinoma (HCC).
  • Previous HCC treatments have shown limited success in the adjuvant setting.
  • A large clinical trial evaluated sorafenib's efficacy after primary tumor treatment.

Discussion:

  • The study found no significant benefit of sorafenib in the adjuvant setting for HCC.
  • Negative results challenge the drug's role in preventing recurrence.
  • Implications for clinical practice and future research directions are considered.

Key Insights:

  • Adjuvant sorafenib failed to demonstrate efficacy in a large-scale hepatocellular carcinoma trial.
  • The antiangiogenic approach may not be beneficial for early-stage HCC.
  • Trial NCT00692770 provides critical data on sorafenib's limitations.

Outlook:

  • Future research should explore alternative adjuvant strategies for HCC.
  • Understanding resistance mechanisms to antiangiogenic drugs is crucial.
  • Re-evaluation of targeted therapy in early-stage HCC is warranted.
Keywords:
Antiangiogenic agentsClinical trialsHepatectomyLocal ablation

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.6K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

6.3K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
494
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K